In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers

Andre C. Felicio, Katherine Dinelle, Pankaj A. Agarwal, Jessamyn Mckenzie, Nicole Heffernan, Jeremy D. Road, Silke Appel-Cresswell, Zbigniew K. Wszolek, Matthew J. Farrer, Michael Schulzer, Vesna Sossi, A. Jon Stoessl

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Introduction: We used positron emission tomography (PET) to assess dopaminergic and serotonergic terminal density in three subjects carrying a mutation in the DCT1 gene, two clinically affected with Perry syndrome. Methods: All subjects had brain imaging using 18F-6-fluoro-l-dopa (FDOPA, dopamine synthesis and storage), (+)-11C-dihydrotetrabenazine (DTBZ, vesicular monoamine transporter type 2), and 11C-raclopride (RAC, dopamine D2/D3 receptors). One subject also underwent PET with 11C-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB, serotonin transporter). Results: FDOPA-PET and DTBZ-PET in the affected individuals showed a reduction of striatal tracer uptake. Also, RAC-PET showed higher uptake in these area. DASB-PET showed significant uptake changes in left orbitofrontal cortex, bilateral anterior insula, left dorsolateral prefrontal cortex, left orbitofrontal cortex, left posterior cingulate cortex, left caudate, and left ventral striatum. Conclusions: Our data showed evidence of both striatal dopaminergic and widespread cortical/subcortical serotonergic dysfunctions in individuals carrying a mutation in the DCTN1 gene.

Original languageEnglish (US)
Pages (from-to)1197-1201
Number of pages5
JournalMovement Disorders
Volume29
Issue number9
DOIs
StatePublished - Aug 2014

Keywords

  • Dopaminergic dysfunction
  • Dynactin gene
  • Perry syndrome
  • Positron emission tomography
  • Serotonergic dysfunction

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers'. Together they form a unique fingerprint.

  • Cite this

    Felicio, A. C., Dinelle, K., Agarwal, P. A., Mckenzie, J., Heffernan, N., Road, J. D., Appel-Cresswell, S., Wszolek, Z. K., Farrer, M. J., Schulzer, M., Sossi, V., & Stoessl, A. J. (2014). In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Movement Disorders, 29(9), 1197-1201. https://doi.org/10.1002/mds.25893